podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 17/22 Podcast
  4. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1
Background: Human renal cell carcinoma (RCC) is very resistant to
chemotherapy. ABT-737 is a novel inhibitor of antiapoptotic
proteins of the Bcl-2 family that has shown promise in various
preclinical tumour models. Results: We here report a strong
over-additive pro-apoptotic effect of ABT-737 and etoposide,
vinblastine or paclitaxel but not 5-fluorouracil in cell lines from
human RCC. ABT-737 showed very little activity as a single agent
but killed RCC cells potently when anti-apoptotic Mcl-1 or,
unexpectedly, A1 was targeted by RNAi. This potent augmentation
required endogenous Noxa protein since RNAi directed against Noxa
but not against Bim or Puma reduced apoptosis induction by the
combination of ABT-737 and etoposide or vinblastine. At the level
of mitochondria, etoposide-treatment had a similar sensitizing
activity and allowed for ABT-737-induced release of cytochrome c.
Conclusions: Chemotherapeutic drugs can overcome protection
afforded by Mcl-1 and A1 through endogenous Noxa protein in RCC
cells, and the combination of such drugs with ABT-737 may be a
promising strategy in RCC. Strikingly, A1 emerged in RCC cell lines
as a protein of similar importance as the well-established Mcl-1 in
protection against apoptosis in these cells.

Weitere Episoden

Analysis of IL2/IL21 Gene Variants in Cholestatic Liver Diseases Reveals an Association with Primary Sclerosing Cholangitis

Analysis of IL2/IL21 Gene Variants in Cholestatic Liver Diseases Reveals an Association with Primary Sclerosing Cholangitis

vor 15 Jahren
Biliary Bicarbonate Secretion Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Man

Biliary Bicarbonate Secretion Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Man

vor 15 Jahren
Growth Pattern of Untreated Boys with Simple Virilizing Congenital Adrenal Hyperplasia Indicates Relative Androgen Insensitivity during the First Six Months of Life

Growth Pattern of Untreated Boys with Simple Virilizing Congenital Adrenal Hyperplasia Indicates Relative Androgen Insensitivity during the First Six Months of Life

vor 15 Jahren
Growth Patterns in the First Three Years of Life in Children with Classical Congenital Adrenal Hyperplasia Diagnosed by Newborn Screening and Treated with Low Doses of Hydrocortisone

Growth Patterns in the First Three Years of Life in Children with Classical Congenital Adrenal Hyperplasia Diagnosed by Newborn Screening and Treated with Low Doses of Hydrocortisone

vor 15 Jahren
Missing Heritability in the Tails of Quantitative Traits? A Simulation Study on the Impact of Slightly Altered True Genetic Models

Missing Heritability in the Tails of Quantitative Traits? A Simulation Study on the Impact of Slightly Altered True Genetic Models

vor 15 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Er
Erasmus2

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz